NCT04415164

Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Xueshuantong Lyophilized Powder in Chinese Patients With Acute Ischemic Stroke

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 480 (estimated)
• Sponsor: Dongzhimen Hospital, Beijing · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim is to assess the effects and harms of Xueshuantong lyophilized powder versus placebo in patients with acute ischemic stroke when initiated within 72 hours of symptom onset.

Conditions

• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Xueshuantong lyophilized powder	Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
DRUG	Placebo	Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
OTHER	Guidelines-based standard care	Guidelines-based standard care for acute ischemic stroke

Timeline

• Start date: 2020-09-29
• Primary completion: 2022-10-31
• Completion: 2023-05-31
• First posted: 2020-06-04
• Last updated: 2021-04-09

Locations

1 site across 1 country: China